appropri
diagnosi
key
factor
treatment
viral
diseas
time
import
factor
rapidli
develop
epidemiolog
danger
diseas
influenza
ebola
sar
chronic
viral
diseas
hcv
asymptomat
oligosymptomat
therapeut
success
mainli
depend
earli
detect
infect
agent
last
year
aptam
technolog
use
wide
rang
diagnost
therapeut
applic
concret
sever
strategi
current
explor
use
aptam
viru
protein
diagnost
point
view
aptam
design
biorecognit
element
diagnost
system
detect
viral
protein
either
blood
serum
plasma
infect
cell
anoth
potenti
use
aptam
therapeut
viral
infect
interf
interact
viru
host
use
aptam
target
hostcel
matrix
receptor
attack
viru
intracellularli
target
protein
implic
viral
replic
cycl
paper
review
aptam
work
viral
protein
discov
focu
recent
advanc
improv
aptam
properti
real
tool
viral
infect
detect
treatment
virus
infecti
agent
enter
replic
insid
live
cell
organ
viru
replic
insid
cell
may
remain
dormant
long
period
time
releas
immedi
attach
healthi
cell
begin
infect
process
mani
diseas
caus
virus
influenza
hepat
human
immunodefici
viru
hiv
emerg
viral
diseas
differ
symptom
fever
weak
present
symptom
rapid
secur
diagnosi
viral
infect
key
factor
treatment
diseas
avoid
new
spread
virus
caus
differ
type
damag
bodi
left
untreat
lead
death
mani
antivir
drug
block
infect
process
differ
stage
drug
prevent
viru
interact
healthi
cell
block
receptor
help
intern
viru
cell
drug
inhibit
prolifer
viru
within
cell
simultan
use
sever
drug
affect
differ
process
increas
probabl
recoveri
patient
although
viral
infect
hepat
hiv
remain
latent
long
time
current
treatment
control
viru
prevent
damag
bodi
viral
infect
usual
produc
immun
respons
host
elimin
infect
viru
protect
effect
produc
vaccin
confer
artifici
acquir
immun
viral
infect
howev
virus
includ
caus
acquir
immun
defici
syndrom
aid
viral
hepat
evad
immun
respons
result
chronic
infect
antibiot
effect
virus
sever
antivir
drug
develop
virus
use
vital
metabol
pathway
within
host
cell
replic
difficult
elimin
without
use
drug
caus
toxic
effect
host
cell
gener
effect
medic
approach
viral
diseas
vaccin
provid
immun
infect
antivir
drug
select
interfer
viral
replic
antivir
drug
nucleosid
analogu
lack
hydroxyl
group
virus
mistakenli
incorpor
analogu
genom
replic
consequ
newli
synthes
dna
inact
lifecycl
viru
halt
frequent
prescrib
antivir
nucleosid
analogu
baseddrug
aciclovir
herp
simplex
viru
infect
lamivudin
hiv
hepat
b
viru
infect
last
year
nucleosid
analogu
drug
ribavirin
combin
interferon
use
hepat
c
treatment
although
current
effect
treatment
includ
simeprevir
avail
patient
genotyp
genotyp
treatment
chronic
carrier
hepat
b
viru
mean
similar
strategi
use
lamivudin
develop
today
first
line
treatment
choic
includ
one
three
drug
pegifn
entecavir
tenofovir
greater
power
produc
low
rate
resist
novel
antivir
agent
emerg
field
vitro
select
nucleic
acid
aptam
aptam
singlestrand
fold
nucleic
acid
rna
ssdna
abl
specif
recogn
target
molecul
high
affin
term
aptam
deriv
latin
word
aptu
mean
fit
firstli
introduc
nobel
laureat
szostak
ellington
describ
vitro
select
rna
molecul
bind
specif
varieti
organ
dye
vitro
process
call
selex
systemat
evolut
ligand
exponenti
enrich
develop
gold
tuerk
selex
process
begin
synthesi
oligonucleotid
librari
consist
central
region
random
sequenc
flank
constant
end
serv
primer
figur
everi
member
librari
linear
oligonucleotid
uniqu
sequenc
acquir
threedimension
structur
depend
experiment
condit
ph
ionic
strength
temperatur
etc
presenc
ligand
highli
structur
aptam
capabl
bind
target
high
affin
specif
divers
oligonucleotid
librari
depend
number
random
nucleotid
contain
oligonucleotid
molecul
thu
oligonucleotid
librari
whose
molecul
contain
random
sequenc
nucleotid
would
repres
differ
sequenc
howev
practic
term
complex
combinatori
librari
oligonucleotid
limit
differ
individu
sequenc
first
select
step
impli
incub
target
molecul
initi
librari
optim
condit
temperatur
ph
salt
concentr
final
use
aptam
select
step
subpopul
individu
sequenc
specif
interact
target
molecul
enrich
subpopul
isol
physicochem
techniqu
subsequ
bound
sequenc
elut
amplifi
next
round
select
stringenc
select
condit
may
increas
identifi
tightestbind
sequenc
iter
round
perform
popul
enrich
sequenc
display
high
affin
specif
target
figur
last
year
sever
modifi
selex
process
arisen
allow
adapt
technolog
differ
target
whole
cell
small
molecul
organ
dye
peptid
etc
differ
final
applic
final
point
select
aptam
produc
chemic
synthesi
purifi
high
degre
therefor
elimin
batchtobatch
variat
found
use
antibodi
main
advantag
aptam
relat
antibodi
summar
tabl
tabl
main
advantag
aptam
antibodi
aptam
identifi
vitro
process
selex
select
condit
manipul
obtain
aptam
stabl
wide
rang
environment
condit
aptam
may
obtain
nonimmunogen
protein
toxin
aptam
produc
chemic
synthesi
littl
batch
batch
variat
aptam
modifi
increas
stabil
report
molecul
attach
aptam
precis
locat
involv
bind
aptam
oligonucleotid
amplifi
easili
detect
denatur
aptam
regener
within
minut
aptam
stabl
long
term
storag
transport
ambient
temperatur
immunogen
small
size
allow
effici
entri
cell
compart
last
year
sever
modifi
selex
process
arisen
allow
adapt
technolog
differ
target
whole
cell
small
molecul
organ
dye
peptid
etc
differ
final
applic
final
point
select
aptam
produc
chemic
synthesi
purifi
high
degre
therefor
elimin
batchtobatch
variat
found
use
antibodi
main
advantag
aptam
relat
antibodi
summar
tabl
rna
dna
aptam
specif
characterist
would
give
advantag
differ
applic
instanc
process
select
dna
aptam
shorter
chemic
synthesi
dna
oligom
cheaper
easier
rna
oligom
addit
dna
aptam
usual
greater
chemic
stabil
longer
shelf
life
rna
oligom
resist
nucleas
activ
insid
live
organ
characterist
would
seem
confer
dna
aptam
import
advantag
use
howev
rna
aptam
seem
greater
flexibl
come
fold
acquir
tertiari
structur
genet
encod
express
directli
target
cell
organ
although
commonli
accept
rna
aptam
prefer
use
therapi
dna
aptam
preferenti
use
diagnost
tool
except
nonwrot
rule
individu
aptam
modifi
order
improv
approach
instanc
chemic
modif
may
introduc
rise
aptam
vivo
stabil
addit
variat
may
need
intend
applic
like
biotin
andor
digoxigenin
label
fluoresc
report
chemic
group
thiol
amin
etc
requir
biosens
diagnost
purpos
moreov
aptam
truncat
elimin
oligonucleotid
sequenc
import
interact
target
correct
threedimension
aptam
structur
identif
truncat
aptam
limit
minimum
domain
interact
requir
consider
effort
even
though
aptam
less
nucleotid
length
alreadi
report
human
immunodefici
viru
lentiviru
subgroup
retroviru
caus
hiv
infect
time
aid
hiv
infect
essenti
cell
human
immun
system
cell
macrophag
dendrit
cell
cell
number
declin
critic
level
cellmedi
immun
lost
bodi
becom
progress
suscept
opportunist
infect
hiv
enter
cell
endocytosi
interact
viral
surfac
protein
su
host
cell
subsequ
interact
complex
chemokin
coreceptor
produc
conform
chang
viral
protein
promot
fusion
virion
target
cell
membran
lead
releas
hiv
particl
cell
insid
cell
viral
uncoat
gener
viral
revers
transcript
complex
revers
transcript
give
hiv
preintegr
complex
pic
pic
get
nucleu
hiv
dna
proviru
integr
cellular
chromosom
integr
lead
either
latent
transcript
activ
form
infect
latent
form
give
viral
latenc
cell
replic
new
infect
cell
proviru
remain
hidden
year
replic
form
new
viral
particl
moment
transcript
activ
form
transcript
translat
form
new
viral
particl
dead
host
cell
goe
infect
new
cell
great
effort
made
get
sensit
fast
simpl
diagnost
method
effect
therapi
present
initi
clinic
test
hiv
human
made
antigenantibodi
combin
immunoassay
detect
antibodi
antigen
screen
establish
infect
acut
infect
enzymelink
immunosorb
assay
elisa
real
time
pcr
method
use
accept
clinic
sampl
aptam
recogn
hiv
protein
like
tat
rev
mainli
use
sever
biosensor
system
base
surfac
plasmon
reson
spr
quartz
crystal
microbal
qcm
techniqu
thu
tombelli
et
al
gener
biosensor
base
spr
qcm
techniqu
introduc
aptam
capabl
detect
tat
protein
use
biotinstreptavidin
interact
approach
allow
high
specif
distinct
tat
rev
hiv
protein
structur
similar
tat
system
target
tat
protein
use
biosensor
base
diamond
fieldeffect
transistor
fet
techniqu
aptabiosensor
high
sensibl
specif
devic
complex
expens
present
treatment
combin
sever
antiretrovir
drug
cart
slow
progress
diseas
reduc
risk
death
diseas
complic
cur
moreov
mani
patient
toler
cart
sever
side
effect
expens
patient
develop
countri
regard
aptam
consid
altern
adjuv
chemic
antivir
agent
cart
overcom
limit
date
highli
specif
nucleic
acidbas
aptam
target
variou
part
genom
protein
includ
proteas
pr
revers
transcriptas
rt
nucleocapsid
gag
cellular
protein
nucleolin
isol
shown
effect
suppress
viral
replic
appli
hiv
therapi
figur
diamond
fieldeffect
transistor
fet
techniqu
aptabiosensor
high
sensibl
specif
devic
complex
expens
present
treatment
combin
sever
antiretrovir
drug
cart
slow
progress
diseas
reduc
risk
death
diseas
complic
cur
moreov
mani
patient
toler
cart
sever
side
effect
expens
patient
develop
countri
regard
aptam
consid
altern
adjuv
chemic
antivir
agent
cart
overcom
limit
date
highli
specif
nucleic
acidbas
aptam
target
variou
part
genom
protein
includ
proteas
pr
revers
transcriptas
rt
nucleocapsid
gag
cellular
protein
nucleolin
isol
shown
effect
suppress
viral
replic
appli
hiv
therapi
figur
hiv
viral
particl
inner
capsid
contain
ssrna
viral
genom
integras
retrotranscriptas
protein
mainli
outer
envelop
protein
involv
interact
cellular
receptor
nl
fusion
cellular
membran
cytoplasm
ssrna
viral
genom
releas
retrotranscript
step
produc
integras
protein
bind
dsdna
viral
genom
ltr
end
sequenc
cellular
protein
form
preintegr
complex
pic
pic
goe
nucleu
nuclear
pore
integr
cellular
genom
integras
protein
activ
proviru
viral
rna
transcript
provir
dna
export
cytoplasm
translat
viral
protein
proteas
big
preprotein
assembl
new
rna
viral
genom
leav
cell
outer
envelop
cellular
membran
bud
viral
particl
proteas
process
big
preprotein
get
matur
viral
particl
long
termin
repeat
ltr
sequenc
necessari
proper
express
viral
gene
interfer
function
rna
domain
either
disrupt
structur
block
interact
viral
cellular
factor
may
serious
compromis
viabil
srisawat
engelk
select
rna
aptam
bind
ltr
dna
hiv
viral
particl
inner
capsid
contain
ssrna
viral
genom
integras
retrotranscriptas
protein
mainli
outer
envelop
protein
involv
interact
cellular
receptor
nl
fusion
cellular
membran
cytoplasm
ssrna
viral
genom
releas
retrotranscript
step
produc
integras
protein
bind
dsdna
viral
genom
ltr
end
sequenc
cellular
protein
form
preintegr
complex
pic
pic
goe
nucleu
nuclear
pore
integr
cellular
genom
integras
protein
activ
proviru
viral
rna
transcript
provir
dna
export
cytoplasm
translat
viral
protein
proteas
big
preprotein
assembl
new
rna
viral
genom
leav
cell
outer
envelop
cellular
membran
bud
viral
particl
proteas
process
big
preprotein
get
matur
viral
particl
long
termin
repeat
ltr
sequenc
necessari
proper
express
viral
gene
interfer
function
rna
domain
either
disrupt
structur
block
interact
viral
cellular
factor
may
serious
compromis
viabil
srisawat
engelk
select
rna
aptam
bind
ltr
dna
show
conserv
segment
present
sever
aptam
could
form
duplex
via
watsoncrick
basepair
prefer
sequenc
one
strand
dna
assum
aptam
invad
duplex
consequ
specif
aptam
would
inhibit
transcript
process
meanwhil
sanchezluqu
et
al
report
vitro
select
specif
rna
aptam
untransl
region
genom
aptam
inhibit
product
human
cell
line
analysi
select
sequenc
structur
allow
identif
highli
conserv
ntlong
stemloop
motif
contain
common
ntlong
apic
loop
produc
inhibit
close
thu
constitut
shortest
rna
molecul
far
describ
effici
interfer
replic
reason
use
rna
aptam
go
cell
dna
plasmid
get
intracellular
express
rna
aptam
block
target
aptam
proteas
pr
life
cycl
hiv
must
success
complet
sever
key
step
order
replic
host
environ
one
critic
step
involv
process
gag
gagpol
polyprotein
precursor
matur
function
compon
viral
matur
function
provid
viral
encod
aspartyl
proteas
pr
thought
occur
either
immedi
bud
activ
form
protein
kda
homodim
consist
two
acid
long
subunit
contribut
catalyt
aspart
residu
activ
site
inhibit
proteolyt
activ
pr
lead
product
immatur
noninfecti
particl
duclair
et
al
develop
rna
aptam
viral
proteas
inhibit
hiv
replic
vitro
sever
small
aptam
contain
gquadruplex
select
hiv
protein
demonstr
antivir
activ
viral
enzym
integras
essenti
retrovir
replic
catalyz
integr
newli
synthes
doublestrand
viral
dna
genom
host
genom
ojwang
et
al
obtain
modifi
aptam
name
abl
inhibit
integras
activ
valu
nanomolar
rang
first
inhibitor
test
clinic
trial
develop
aronex
pharmaceut
woodland
tx
usa
deriv
stabl
parent
molecul
also
capabl
effici
inhibit
replic
cell
cultur
later
develop
revers
transcriptas
two
enzymat
activ
dna
polymeras
activ
copi
either
dna
rna
templat
rnase
h
cleav
rna
rna
part
rnadna
duplex
two
enzymat
function
rt
polymeras
rnase
h
cooper
convert
rna
doublestrand
linear
dna
destefano
nair
confirm
vitro
effect
dna
aptam
name
direct
revers
transcriptas
hiv
strain
aptam
compet
natur
templat
bind
site
enzym
subsequ
produc
inhibit
viral
replic
parallel
michalowski
et
al
identifi
three
aptam
contain
bimodular
structur
compris
stemloop
modul
link
gquadruplex
addit
author
demonstr
dna
aptam
inhibit
rt
divers
primat
lentivirus
low
nm
ic
valu
anoth
interest
approach
inhibit
rnase
h
activ
associ
rt
purpos
andreola
et
al
identifi
two
dna
aptam
grich
sequenc
name
odn
capabl
form
structur
aptam
inhibit
rnase
h
activ
rt
vitro
ic
valu
submicromolar
rang
effect
observ
cellular
rnase
h
shorter
dna
aptam
deriv
odn
name
maintain
capabl
form
stabl
structur
abl
inhibit
also
integras
nanomolar
rang
nucleocapsid
nc
protein
play
import
role
encapsid
viral
rna
assembl
viral
particl
progress
viral
infect
prevent
inhibit
nucleocapsid
synthesi
sinc
nc
protein
resist
mutat
might
excel
target
antivir
therapi
kim
et
al
isol
rna
aptam
bind
matur
form
nc
protein
high
affin
compet
packag
element
psi
rna
bind
nc
protein
author
suggest
stabil
rna
aptam
expect
act
inhibitor
viral
packag
aptam
surfac
glycoprotein
gp
essenti
viru
entri
cell
play
vital
role
attach
specif
cell
surfac
receptor
mainli
helper
tcell
sever
small
aptam
contain
gquadruplex
select
demonstr
antivir
activ
first
molecul
phosphorothio
ttggggtt
name
isi
form
tetramer
gquadruplex
structur
bind
loop
inhibit
viru
entri
later
koizumi
et
al
synthes
set
grich
oligonucleotid
identifi
hexadeosyribonucleotid
tgggag
known
hotoda
sequenc
sever
author
use
hotoda
sequenc
lead
sequenc
make
seri
modif
end
molecul
mutat
sequenc
allow
find
molecul
high
antihiv
activ
khati
et
al
dey
et
al
two
year
later
describ
isol
fluoropyrimidinesubstitut
rna
aptam
bind
specif
surfac
glycoprotein
gp
potent
neutral
infect
human
peripher
blood
mononuclear
cell
one
aptam
truncat
form
structur
character
shortli
later
author
show
aptam
bind
site
rel
manner
provid
mechanist
explan
neutral
potenc
typic
therapeut
target
gag
polyprotein
low
variabl
compar
sequenc
genom
two
aptam
develop
protein
thu
lochri
et
al
isol
rna
ligand
bind
gag
protein
region
correspond
matrix
protein
nucleocapsid
nc
protein
interestingli
although
sequenc
aptam
differ
rna
packag
element
psi
bound
nc
region
interf
bind
psi
year
later
ramalingam
et
al
select
new
rna
aptam
gag
protein
name
aptam
display
inhibit
extracellular
capsid
level
reduc
cellular
level
mrna
gag
probabl
perturb
specif
gaggenom
rna
interact
result
suggest
rna
aptam
may
provid
novel
method
inhibit
hiv
replic
anoth
strategi
block
hiv
infect
target
human
protein
host
cell
like
cell
coreceptor
inhibit
hiv
entranc
host
cell
may
less
side
effect
commonli
use
cc
chemokin
receptor
type
cxc
chemokin
receptor
type
coreceptor
along
enter
target
cell
human
import
coreceptor
macrophagetrop
viru
express
tcell
macrophag
differ
associ
resist
suscept
essenti
factor
viral
entri
repres
attract
cellular
target
treatment
thu
zhou
et
al
report
select
rna
aptam
use
high
throughput
sequenc
ht
analyz
rna
pool
select
round
individu
sequenc
classifi
six
major
group
group
group
share
conserv
sequenc
compris
nucleotid
uucgucug
ug
g
name
activ
studi
prophylact
experi
determin
whether
aptam
would
block
hiv
infect
virus
cell
cultur
result
show
aptam
effici
neutral
infect
strain
ic
nm
aptam
nucleolin
ncl
nucleolin
ncl
multifunct
cellular
protein
overexpress
cancer
cell
membran
ncl
involv
initi
step
virioncel
recognit
ncl
cellular
fraction
contain
hiv
genom
viral
matrix
revers
transcriptas
addit
complex
cell
membran
support
potenti
role
protein
viral
entri
absenc
cellular
receptor
attach
occur
coordin
interact
heparan
sulfat
proteoglycan
cellsurfaceexpress
ncl
grich
aptam
form
stabl
gquadruplex
structur
display
antineoplast
properti
vitro
vivo
major
molecular
target
ncl
perron
et
al
test
whether
aptam
abl
interfer
cellular
entri
use
differ
strain
host
cell
variou
time
postinfect
result
demonstr
effici
inhibit
attachmententri
host
cell
absenc
cytotox
test
dose
aptam
also
serv
element
select
recogn
bind
defin
cell
type
tissu
attach
drug
molecul
aptam
use
deliv
cargo
molecul
specif
cell
tissu
interest
order
reach
effici
rnai
activ
aptamersirna
conjug
must
success
intern
releas
cytoplasm
meet
rnai
machineri
improv
dicer
entri
process
sirna
one
pair
complementari
guanosin
cytosin
gc
rich
sticki
bridg
sequenc
chemic
append
end
aptam
one
sirna
strand
respect
aptam
sirna
portion
chemic
synthes
subsequ
anneal
via
sticki
bridg
either
coval
conjug
physic
assembl
differ
sirna
molecul
success
function
aptam
receptor
achiev
target
rnai
efficaci
reli
specif
interact
aptam
receptor
express
target
cell
tissu
zhou
et
al
isol
rna
aptam
bal
protein
use
creat
seri
dual
inhibitori
function
aptamersirna
chimera
author
also
demonstr
one
aptamersirna
chimera
specif
taken
cell
express
attach
sirna
process
dicer
result
specif
inhibit
replic
infect
cultur
cem
tcell
primari
blood
mononuclear
cell
pbmc
interestingli
aptam
sirna
portion
aptamersirna
chimera
potent
antihiv
activ
final
author
test
antivir
activ
chimer
rna
human
mous
model
multilineag
human
hematopoiesi
show
treatment
either
aptam
aptamersirna
chimera
suppress
replic
sever
order
magnitud
prevent
viralinduc
helper
cell
declin
order
improv
util
aptam
sirna
deliveri
vehicl
author
chemic
synthes
modifi
aptam
complex
three
differ
sirna
tatrev
two
host
cell
protein
result
effect
deliveri
sirna
vivo
knockdown
target
mrna
potent
inhibit
replic
human
mous
model
interestingli
follow
end
aptamersirna
cocktail
treatment
hiv
level
rebound
facilit
followup
treatment
aptam
cocktail
sirna
result
complet
suppress
viral
load
extend
sever
week
beyond
final
inject
anoth
interest
approach
target
deliveri
develop
zhu
et
al
work
author
show
dna
aptam
obtain
convers
previous
report
rna
aptam
could
use
deliv
sirna
cell
specif
dna
aptam
coval
conjug
sens
strand
sirna
target
proteas
hivpr
result
dna
aptamersirna
chimera
specif
enter
cell
effici
knockdown
express
exogen
hivpr
gene
studi
demonstr
dna
aptam
intrins
stabil
greater
potenti
use
sirna
deliveri
tabl
show
inform
aptam
describ
hiv
direct
applic
use
aptamersirna
chimera
propos
wheeler
et
al
demonstr
aptamersirna
chimera
specif
block
gene
express
cell
macrophag
vitro
polar
cervicovagin
tissu
explant
femal
genit
tract
human
mice
thu
could
use
activ
element
microbicid
avoid
hiv
sexual
transmiss
summari
interest
result
point
use
aptam
develop
novel
therapi
hepat
b
viru
hbv
partial
doublestrand
dna
viru
hepadnavirida
famili
classifi
eight
genotyp
h
main
element
viral
particl
hbv
viru
also
character
compon
hepat
b
surfac
antigen
hbsag
one
current
object
diagnost
hbv
develop
daili
screen
assay
short
period
detect
infect
recognit
therefor
suh
et
al
develop
fast
low
cost
detect
test
base
competit
bind
assay
combin
fluoresc
reson
energi
transfer
fret
assay
built
aptam
select
hepat
b
viru
surfac
antigen
hbsag
best
character
frequent
use
hbv
marker
describ
aptasensor
approxim
sensit
convent
method
new
set
three
differ
dna
aptam
select
hbsag
appli
develop
chemiluminesc
platform
new
aptasensor
design
aptamersconjug
magnet
nanoparticl
reach
detect
limit
fivefold
better
current
enzymelink
immunosorb
assay
elisa
kit
use
hospit
last
year
differ
strategi
inhibit
hbv
activ
describ
use
aptam
select
divers
viral
target
protein
first
liu
et
al
propos
therapeut
tool
rna
aptam
select
hbsag
protein
abl
discrimin
hbsagexpress
liver
cell
hbsagneg
cell
later
feng
et
al
describ
innov
strategi
fight
hbv
infect
suppress
ribonucleoprotein
complex
interact
revers
transcriptas
name
p
protein
rna
stemloop
purpos
isol
individu
rna
aptam
high
affin
recombin
truncat
hbv
p
protein
compet
rna
interact
without
cytotox
effect
cultur
cell
suggest
potenti
antivir
activ
describ
aptam
hand
zhang
et
al
chosen
hbv
core
protein
hbvc
target
isol
dna
aptam
inhibit
nucleocapsid
format
shown
select
aptam
prevent
nucleocapsid
assembl
viral
replic
hepat
cellular
line
final
orabi
et
al
isol
dna
aptam
recogn
specif
matrix
bind
domain
mbd
domain
mutat
residu
one
isol
aptam
propos
therapi
molecul
inhibit
virion
product
interf
interact
matrix
domain
mbd
tabl
show
inform
aptam
describ
hbv
hcv
viral
genom
positivestrand
rna
contain
approxim
kilobas
codifi
polyprotein
around
amino
acid
hcv
polyprotein
matur
process
mediat
proteas
give
rise
viral
protein
four
structur
c
six
nonstructur
date
three
protein
use
antivir
target
isol
specif
aptam
aptamerbas
biosensor
promis
diagnost
platform
allow
hcv
infect
detect
earli
stage
immunosuppress
patient
thu
differ
group
develop
divers
aptasensor
improv
diagnost
assay
hcv
infect
first
lee
et
al
develop
biosensor
prototyp
specif
recogn
hcv
core
protein
sera
infect
patient
use
select
rna
aptam
core
antigen
hcv
viral
particl
retain
f
aptam
immobil
plate
detect
sequenti
step
anticor
secondari
antibodi
later
chen
et
al
develop
earli
diagnost
assay
base
sandwichelisa
recogn
hcv
viral
protein
use
biotinlabel
dna
aptam
hcv
envelop
glycoprotein
obtain
result
infect
patient
show
good
correl
viral
genom
quantif
assay
hcv
antibodi
detect
sandwichelisa
aptasensor
afterward
shi
et
al
develop
similar
platform
earli
detect
coat
bottom
well
dna
aptam
hcv
core
label
biotin
hcvcore
antibodi
conjug
horseradish
peroxidas
hrp
appli
surfac
platform
appli
detect
protein
sera
hcvinfect
patient
show
proport
relationship
amplifi
rna
copi
hcv
core
protein
concentr
moreov
wang
et
al
design
rapid
easytous
diagnost
platform
compos
later
flow
strip
treat
thioldna
aptam
hcv
core
antigen
hcv
elisa
assay
core
aptam
later
flow
strip
show
posit
coincid
rate
compar
hcv
rna
amplif
assay
effort
develop
diagnost
test
monitor
infect
hcv
sampl
park
et
al
design
elisalik
assay
replac
captur
detect
antibodi
dna
aptam
select
hcv
enzym
link
aptosorb
assay
elasa
describ
use
qualit
quantit
analysi
viru
infect
sampl
two
laboratori
develop
labelfre
aptasensor
elimin
label
step
simplifi
hcv
detect
method
hwang
et
al
describ
highli
sensit
labelfre
aptasensor
base
nanomechan
microcantilev
biosensor
abl
measur
surfac
stress
due
interact
immobil
rna
aptam
hcv
helicas
hand
roh
et
al
develop
labelfre
diagnost
platform
detect
quantifi
presenc
hcv
polymeras
viral
protein
use
conjug
streptavidinbiotin
rna
aptam
octet
biosensor
erad
hcv
diseas
one
main
object
global
public
health
current
hcv
infect
patient
treat
combin
proteas
inhibitor
telaprevir
tvr
boceprevir
boc
pegylatedinterferon
ribavirin
howev
new
directact
antivir
daa
tvr
boc
gener
high
rate
side
effect
expens
also
suscept
new
resist
virus
therefor
necessari
develop
new
daa
treatment
effect
fewer
side
effect
current
therapi
end
differ
advanc
made
base
aptam
hcv
host
cell
protein
therapi
figur
amplif
assay
effort
develop
diagnost
test
monitor
infect
hcv
sampl
park
et
al
design
elisalik
assay
replac
captur
detect
antibodi
dna
aptam
select
hcv
enzym
link
aptosorb
assay
elasa
describ
use
qualit
quantit
analysi
viru
infect
sampl
two
laboratori
develop
labelfre
aptasensor
elimin
label
step
simplifi
hcv
detect
method
hwang
et
al
describ
highli
sensit
labelfre
aptasensor
base
nanomechan
microcantilev
biosensor
abl
measur
surfac
stress
due
interact
immobil
rna
aptam
hcv
helicas
hand
roh
et
al
develop
labelfre
diagnost
platform
detect
quantifi
presenc
hcv
polymeras
viral
protein
use
conjug
streptavidinbiotin
rna
aptam
octet
biosensor
erad
hcv
diseas
one
main
object
global
public
health
current
hcv
infect
patient
treat
combin
proteas
inhibitor
telaprevir
tvr
boceprevir
boc
pegylatedinterferon
ribavirin
howev
new
directact
antivir
daa
tvr
boc
gener
high
rate
side
effect
expens
also
suscept
new
resist
virus
therefor
necessari
develop
new
daa
treatment
effect
fewer
side
effect
current
therapi
end
differ
advanc
made
base
aptam
hcv
host
cell
protein
therapi
figur
nontransl
region
highli
conserv
sequenc
structur
region
close
relat
transcript
replic
hcv
viru
specif
end
contain
intern
nontransl
region
highli
conserv
sequenc
structur
region
close
relat
transcript
replic
hcv
viru
specif
end
contain
intern
ribosom
entri
site
ire
domain
respons
transcript
initi
ribosom
recognit
hcv
viral
genom
howev
utr
includ
region
essenti
viral
replic
name
cisact
replic
element
cre
et
al
decid
use
subdomain
iiid
ire
element
antivir
target
select
rna
aptam
verifi
isol
aptam
inhibit
hcv
translat
vitro
cell
cultur
year
kikuchi
et
al
isol
rna
aptam
capabl
bind
domain
ii
hcv
ire
show
iresmedi
vitro
translat
reduc
use
aptam
later
isol
new
rna
aptam
popul
hcv
ire
domain
iiiiv
corrobor
aptam
high
inhibitori
effect
iresmedi
translat
vitro
vivo
improv
inhibitori
effect
select
aptam
construct
two
new
molecul
name
compos
aptam
link
end
fuse
aptam
recogn
two
differ
subdomain
ire
element
least
time
effici
parent
aptam
inhibit
mrna
iresdepend
translat
vitro
follow
ire
antivir
target
et
al
describ
innov
vitro
select
method
isol
aptam
fuse
hammerhead
ribozym
capac
inhibit
rna
translat
mediat
ire
select
chimer
aptamerribozym
abl
recogn
ire
element
cleavag
end
nucleotid
posit
success
combin
two
function
element
molecul
shown
select
chimer
molecul
thu
aptamerribozym
chimera
anchor
domain
iv
ire
element
inhibit
vitro
vivo
iresmedi
translat
therefor
recruit
ribosom
particl
mediat
ire
element
inhibit
chimera
prevent
translat
replic
hepat
cell
line
moreov
avoid
hcv
genom
replic
konno
et
al
isol
rna
aptam
end
neg
strand
viru
genom
interestingli
rna
aptam
name
abl
recogn
minusir
region
reduc
positivestrand
genom
rna
synthesi
inhibit
hcv
replic
marton
et
al
select
rna
aptam
cre
element
abl
repress
replic
hcv
replicon
hepat
cell
subsequ
two
select
aptam
interact
subdomain
cre
element
produc
structur
reorgan
end
hcv
genom
signific
decreas
hcv
replic
vivo
aptam
nonstructur
protein
protein
remark
hcv
target
develop
directact
antivir
due
fact
protein
implic
hcv
replic
essenti
viral
cycl
recent
gao
et
al
isol
dna
aptam
specif
shown
aptam
inhibit
viral
particl
product
result
ntermin
protein
domain
interact
prevent
complex
multifunct
enzym
essenti
protein
viru
surviv
consid
good
target
develop
new
antiviraldrug
proteas
activ
protein
found
ntermin
domain
helicas
activ
present
ctermin
domain
enzym
last
year
group
nishikawa
work
differ
set
rna
aptam
fulllength
truncat
protein
inhibit
dualact
initi
isol
aptam
inhibit
proteas
activ
dual
activ
proteasehelicas
enzym
afterward
new
rna
aptam
helicas
domain
protein
name
ii
iii
abl
inhibit
proteas
activ
vitro
later
author
describ
interact
aptam
residu
truncat
form
put
target
proteas
activ
inhibit
stabil
protect
aptam
exonucleas
activ
vivo
nishikawa
et
al
conjug
aptam
stem
iv
region
hepat
delta
viru
hdv
ribozym
addit
allow
nuclear
export
aptam
chimer
molecul
ha
fuse
constitut
transport
element
cte
gener
hac
molecul
final
proteaseinhibit
capabl
aptam
check
use
ha
hac
express
vector
vivo
order
inhibit
dual
activ
poli
u
tail
end
aptam
ad
two
construct
abl
inhibit
high
effici
proteas
helicas
activ
moreov
decreas
interact
protein
end
posit
neg
sens
hcv
rna
inhibit
proteas
activ
vivo
next
new
set
rna
aptam
select
helicas
domain
use
truncat
protein
aptam
greatest
capabl
deplet
helicas
activ
vitro
identifi
name
aptam
final
dualfunct
aptam
name
design
use
truncat
version
aptam
plu
aptam
link
mer
poli
u
spacer
design
molecul
show
signific
inhibit
helicaseproteas
activ
vivo
propos
nishikawa
group
best
candid
antihcv
therapi
report
protein
essenti
hcv
product
replic
recent
yu
et
al
isol
character
dna
aptam
hcv
protein
particularli
select
aptam
abl
inhibit
hcv
viru
infect
prevent
proteinprotein
interact
core
protein
aptam
nonstructur
protein
hcv
nonstructur
protein
rnadepend
rna
polymeras
protein
rdrp
respons
gener
positivesens
genom
hcv
rna
negativesens
rna
templat
reduct
hcv
polymeras
activ
affect
hcv
viral
life
cycl
one
main
object
isol
aptam
thu
biroccio
et
al
identifi
specif
rna
aptam
truncat
protein
without
ctermin
region
one
select
aptam
block
rna
transcript
compet
complex
rdrprna
use
differ
bind
site
rna
templat
protein
way
bellecav
et
al
select
dna
aptam
viral
protein
one
chosen
aptam
compet
posit
neg
sens
hcv
viral
rna
bind
rdrp
polymeras
block
initi
elong
step
rna
transcript
howev
aptam
partial
compet
dissoci
rdrprna
complex
format
inhibit
initi
step
hcv
transcript
moreov
interfer
viral
product
transcript
inhibit
hcv
viru
confirm
vivo
use
aptam
tabl
show
inform
aptam
describ
hcv
five
year
later
anoth
set
rna
aptam
protein
obtain
lee
et
al
avoid
aptam
degrad
oligonucleotid
modifi
hydroxyl
roh
fluoropyrimidin
rf
roh
aptam
block
rna
synthesi
hcv
replicon
cell
cultur
without
emerg
viru
escap
mutant
cellular
toxic
hand
rf
oligonucleotid
truncat
conjug
cholesterolor
galactosepeg
molecul
allow
direct
specif
liver
deliveri
cell
tissu
cholesteroland
galpegrf
conjug
aptam
block
rna
synthesi
hcv
genom
mention
aptam
nongenotypespecif
howev
jone
et
al
describ
first
time
aptam
protein
exclus
recogn
inhibit
rnapolymeras
activ
hcv
viru
subtyp
envelop
glycoprotein
put
target
therapi
due
role
hcv
viral
recognit
enter
hepat
cell
chen
et
al
isol
dna
aptam
glycoprotein
select
aptam
higher
affin
genotyp
other
strongli
prevent
hcv
viral
infect
cell
afterward
yang
et
al
describ
potenti
antivir
action
dna
aptam
select
protein
hcv
infect
suppress
cell
without
innat
immun
respons
action
case
core
essenti
protein
hcv
viral
assembl
shi
et
al
appli
therapi
abovement
aptam
diagnost
cell
aptam
hcv
core
protein
repress
viral
product
result
defect
assembl
viru
particl
without
stimul
innat
immun
respons
final
innov
approach
inhibit
hcv
viral
infect
design
base
sequestr
implic
regul
fattyacid
metabol
mammal
exclus
infect
cell
end
lee
et
al
gener
chimer
molecul
compos
hammerhead
ribozym
conjug
aptam
protein
aptam
recognit
hcv
infect
ribozym
domain
releas
sequenc
complementari
produc
inhibit
hcv
replic
cell
select
aptam
hcv
shown
good
tool
inhibit
viral
protein
activ
howev
none
test
clinic
trial
necessari
overcom
number
limit
degrad
biodistribut
immun
respons
cellular
intern
nevertheless
recent
public
describ
differ
strategi
overcom
aptam
restrict
use
cholesterol
ribozym
conjug
human
papillomaviru
hpv
dna
viru
papillomaviru
famili
hpv
infect
caus
symptom
resolv
spontan
persist
result
wart
precancer
lesion
increas
risk
cancer
cervix
vulva
vagina
peni
anu
mouth
throat
sever
protein
human
papillomaviru
particularli
promot
tumor
growth
malign
transform
frequent
associ
cervic
cancer
thu
protein
repres
ideal
target
diagnost
therapeut
strategi
belyaeva
et
al
report
two
rna
aptam
name
induc
apoptosi
cell
deriv
cervic
carcinoma
aptam
abl
inhibit
interact
effect
inhibitor
none
inhibit
interact
degrad
toscanogaribay
et
al
isol
aptam
exhibit
specif
kd
compar
aptam
direct
small
target
may
use
detect
papillomaviru
infect
cervic
cancer
group
character
rna
aptam
name
recogn
baculovirusproduc
viruslik
particl
vlp
high
specif
affin
kd
pm
aptam
produc
specif
stabl
bind
vlp
even
biofluid
protein
mix
thu
may
provid
potenti
diagnost
tool
activ
hpv
infect
recent
graham
zarbl
identifi
sever
dna
aptam
high
affin
specif
nontumorigen
revert
hpvtransform
cervic
cancer
cell
use
identifi
new
biomark
relat
carcinogenesi
produc
hpv
report
show
potenti
benefit
aptam
potenti
diagnost
agent
futur
shown
bind
number
cellular
protein
includ
cell
cycl
control
protein
prb
interest
studi
nicol
et
al
select
rna
aptam
term
high
affin
transfect
aptam
cell
result
induct
apoptosi
consequ
inhibit
cell
prolifer
addit
author
demonstr
bound
ntermin
residu
requir
interact
prb
consequ
disrupt
interact
prb
vitro
furthermor
author
demonstr
enhanc
local
er
reduct
associ
proteasom
degrad
suggest
perturb
normal
traffick
promot
er
retent
differ
purpos
gourronc
et
al
select
rna
aptam
enter
signific
intern
capac
tonsillar
epitheli
cell
htec
addit
although
individu
aptam
intern
primari
htec
similar
effici
one
exhibitedthreefold
better
intern
author
claim
aptam
intern
cell
may
use
deliv
therapeut
agent
associ
malign
herp
simplex
viru
two
member
herpesviru
famili
herpesvirida
infect
epitheli
tissu
invad
nervou
system
becom
latent
unfortun
found
treatment
erad
viru
tabl
show
inform
aptam
describ
hpv
hsv
aptam
technolog
use
corbinlickfett
et
al
identifi
rna
sequenc
capabl
recogn
protein
import
regul
viral
gene
express
selex
procedur
gcrich
rna
sequenc
isol
form
stabl
secondari
structur
therapeut
purpos
gopinath
et
al
isol
two
rna
aptam
ectodomain
gd
protein
play
import
role
viral
entri
host
cell
aptam
specif
bind
gd
protein
high
affin
gd
protein
furthermor
effici
block
interact
gd
protein
target
cell
receptor
hvem
dosedepend
manner
ec
nanomolar
rang
activ
analyz
use
plaqu
assay
result
show
aptam
effici
inhibit
viral
entri
shorter
variant
name
aptam
least
high
affin
specif
abil
interfer
gdhvem
interact
similar
way
moor
et
al
report
isol
character
one
aptam
bind
gd
protein
neutral
infect
hvem
entri
receptor
ic
nm
interestingli
aptam
prevent
infect
may
also
reduc
morbid
associ
major
risk
factor
acquisit
influenza
consid
preval
infecti
diseas
human
three
emerg
influenza
virus
respons
major
pandem
twentieth
centuri
spanish
influenza
viru
asian
influenza
viru
hong
kong
influenza
viru
inde
spanish
influenza
viru
estim
kill
million
peopl
worldwid
recent
highli
pathogen
avian
viru
subtyp
produc
sporad
infect
human
associ
high
rate
mortal
poor
transmiss
human
prevent
extens
spread
among
human
popul
howev
new
influenza
viru
subtyp
emerg
possess
high
transmiss
rel
low
virul
rapidli
spread
across
entir
globe
caus
first
pandem
centuri
subsequ
wit
appear
new
highli
pathogen
avian
viru
subtyp
china
influenza
virus
envelop
rna
viru
famili
orthomyxovirida
virion
surfac
carri
two
membran
glycoprotein
compon
hemagglutinin
ha
neuraminidas
na
central
core
viral
rna
negativesens
genom
fragment
eight
singlestrand
molecul
viral
protein
packag
protect
rna
segment
contain
one
two
gene
code
viral
protein
highli
variabl
surfac
protein
ha
na
use
classifi
influenza
subtyp
combin
hemagglutinin
neuraminidas
mainli
determin
host
organ
viral
infecti
current
ha
na
type
identifi
subtyp
commonli
found
human
detect
rapid
influenza
viru
well
categor
virus
particularli
import
due
high
risk
infect
rapid
propag
high
frequenc
mutat
often
induc
arriv
new
strain
caus
epidem
even
pandem
extens
review
diagnost
strategi
influenza
recent
publish
antibodi
common
probe
use
detect
either
viral
particl
host
antibodi
develop
infect
howev
although
case
antibodi
abl
distinguish
influenza
b
antibodi
differenti
subtyp
influenza
b
report
altern
probe
subtyp
aptam
thu
aptam
hemagglutinin
ha
success
broadli
use
develop
sensor
influenza
detect
ha
express
high
amount
viral
surfac
requir
bind
fusion
host
cell
current
dna
rna
aptam
ha
describ
sinc
select
recombin
hemagglutinin
ha
viru
b
whole
virus
review
misono
kumar
select
rna
aptam
ha
apanama
use
sprbase
selex
gopinath
et
al
gener
two
rna
aptam
intact
influenza
viru
ha
rna
aptam
abl
discrimin
among
b
influenza
virus
recent
advanc
develop
rapid
automat
point
care
devic
diagnosi
subtyp
influenza
viru
sustain
two
fact
rapid
spread
influenzaassoci
virus
caus
seriou
concern
recent
year
ii
subtyp
avian
influenza
viru
aiv
caus
lethal
outbreak
highli
pathogen
avian
influenza
hpai
poultri
fatal
infect
human
case
decad
thu
aptam
gener
found
specif
recent
pandem
influenza
virus
lee
et
al
develop
integr
microfluid
system
use
screen
specif
aptam
influenza
viru
autom
highli
effici
manner
select
aptam
show
specif
sensit
detect
influenza
viru
even
biolog
sampl
throat
swab
later
use
new
approach
fluorescencebas
detect
influenza
viru
use
sandwichbas
aptam
assay
automat
perform
integr
microfluid
system
entir
detect
process
shorten
min
use
chipbas
system
much
faster
convent
viral
cultur
method
limit
detect
significantli
improv
due
high
affin
high
specif
aptam
addit
twoaptam
microfluid
system
time
higher
sensit
convent
serolog
diagnosi
conform
aptam
chang
respons
solvent
composit
includ
ion
type
concentr
ph
temperatur
basi
wang
et
al
develop
microfluid
system
exploit
predict
chang
conform
aptam
previous
use
group
expos
differ
ion
concentr
order
detect
multipl
type
influenza
viru
thu
singl
fluorescentlabel
aptam
abl
identifi
three
differ
influenza
virus
influenza
influenza
b
time
modifi
oper
condit
min
chipbas
aptamerbind
assay
sever
import
advantag
rapid
accur
cheaper
multipleaptam
screen
current
method
aiv
detect
viru
isol
rtpcr
requir
sever
day
expens
equip
reagent
rapid
detect
assay
also
avail
elisa
immunochromatograph
strip
less
sensit
specif
altern
approach
biosensor
technolog
sever
biosensor
develop
detect
aiv
among
biosensor
use
probe
aptam
aptasensor
review
li
lab
highli
specif
dna
aptam
bind
viru
high
affin
select
use
aptam
author
develop
differ
aptasensor
base
surfac
plasmon
reson
spr
quartz
crystal
microbal
qcm
aptasensor
crosslink
polym
hydrogel
sever
aptasensor
base
imped
method
aptasensor
abl
detect
quickli
andor
sensit
antibodybas
biosensor
impedancebas
aptasensor
describ
fu
et
al
lowest
detect
limit
howev
requir
signal
amplif
label
prolong
detect
limit
imped
aptasensor
microfluid
chip
lower
detect
limit
sprbase
aptasensor
sensit
qcm
aptasensor
qcmbase
aptasensor
practic
infield
use
due
qcm
predisposit
environment
nois
major
advantag
imped
aptasensor
gold
nanoparticl
signal
amplif
describ
karash
et
al
requir
small
sampl
volum
cheaper
detect
platform
base
qcm
use
interdigit
electrod
microfluid
chip
recent
nguyen
et
al
develop
sandwichtyp
sprbase
biosensor
detect
virus
use
pair
aptam
select
mixtur
whole
virus
use
multigo
selex
sensit
dual
aptamerbas
system
increas
singleaptam
addit
sensit
addit
enhanc
secondari
aptam
conjug
gold
nanoparticl
sever
aptam
influenza
viru
develop
therapeut
purpos
mainli
target
hemagglutinin
review
figur
aptam
abl
inhibit
entri
viru
cell
block
hemagglutinin
activ
common
techniqu
measur
inhibitori
activ
aptam
vitro
hemagglutin
inhibit
assay
model
extens
use
test
effect
aptam
viral
infect
involv
use
cell
cultur
mainli
madindarbi
canin
kidney
mdck
cell
cell
infect
viru
incub
aptam
inhibit
viral
infect
test
use
assay
dna
rna
aptam
select
ha
influenza
viru
avian
influenza
viru
abl
significantli
decreas
viral
infect
cell
describ
howev
studi
describ
aptam
capabl
mediat
reduct
viral
pathogen
mice
model
jeon
et
al
evalu
effect
administr
intranas
aptam
dna
aptam
select
ha
peptid
mice
time
viru
infect
aptamerinduc
inhibit
viral
infect
determin
prevent
weight
loss
decreas
viral
load
lung
restrict
level
inflamm
cellular
infiltr
reduc
infect
strain
test
effect
administ
concomitantli
viral
infect
lead
reduct
viral
burden
administr
one
day
prior
infect
prevent
treatment
less
effect
probabl
dna
partial
degrad
interestingli
treatment
two
day
follow
infect
therapeut
treatment
still
lead
almost
reduct
viral
titer
lung
mice
musafia
et
al
use
aptam
start
point
quantit
structureact
relationship
qsar
tool
produc
aptam
time
potent
antivir
activ
anim
model
aptam
bind
aptam
viru
time
higher
may
necessarili
sequencespecif
import
properti
aptam
length
repeat
sequenc
c
nucleotid
aptam
target
pa
polymeras
subunit
also
studi
nonstructur
protein
small
size
amino
acid
molecular
weight
kda
view
interact
rna
viral
cellular
protein
implic
mani
alter
occur
influenza
viru
infect
moreov
antiinterferon
ifn
properti
lead
inhibit
host
innat
immun
thu
import
viral
infect
make
attract
therapeut
target
woo
et
al
select
dna
aptam
specif
induc
product
inhibit
function
addit
select
aptam
abl
inhibit
viral
replic
without
affect
cell
viabil
anoth
antivir
strategi
inhibit
enzym
involv
viral
replic
transcript
translat
polymeras
complex
influenza
viru
catalyz
viral
replic
transcript
heterotrim
compos
three
subunit
name
pa
pa
play
role
endonucleas
cleav
host
mrna
downstream
mrna
cap
structur
recogn
bound
ntermin
pa
subunit
pa
n
hold
endonucleas
activ
site
highli
conserv
among
differ
subtyp
influenza
viru
suggest
attract
target
develop
antiinfluenza
agent
yuan
et
al
select
dna
aptam
pa
protein
three
aptam
pa
n
domain
six
aptam
viru
strain
four
six
pa
n
select
aptam
inhibit
endonucleas
activ
viru
infect
wherea
three
paselect
aptam
inhibit
endonucleas
activ
viru
infect
final
one
four
effect
aptam
exhibit
crossprotect
infect
influenza
virus
inhibitori
concentr
ic
around
nm
pharmaceut
aptam
exhibit
crossprotect
infect
influenza
virus
inhibitori
concentr
around
nm
associ
viral
polymeras
bound
cap
may
involv
preferenti
translat
viral
mrna
influenza
infect
addit
interact
bound
conserv
region
utr
element
viral
mrna
could
promot
format
close
loop
end
viral
mrna
rigi
cytosol
receptor
nonself
rna
mediat
immun
respons
viral
infect
product
mitochondri
antiviralsign
mav
protein
tabl
show
inform
aptam
describ
influenza
viru
vaccin
power
approach
diminish
effect
influenza
epidem
use
antivir
drug
also
use
particularli
delay
spread
new
pandem
virus
neuraminidas
inhibitor
like
oseltamivir
laninamivir
zanamivir
peramivir
commonli
use
antivir
agent
treat
influenza
infect
especi
japan
howev
rapid
increas
drugresist
influenza
viru
essenti
develop
new
antivir
drug
emerg
strategi
block
cellular
factor
import
infect
cycl
advantag
block
import
cellular
pathway
viru
inhibitori
effect
principl
specif
influenza
strain
emerg
resist
viru
minim
limit
number
aptam
target
host
cell
factor
describ
use
rigi
target
aptam
control
viral
infect
emphas
rigi
cytosol
receptor
nonself
rna
mediat
immun
respons
viral
infect
product
use
specif
rigi
aptam
activ
rigi
effici
block
replic
newcastl
diseas
viru
vesicular
stomat
viru
influenza
viru
infect
cell
evidenc
aptam
target
cellular
factor
act
effici
antivir
agent
associ
viral
polymeras
bound
cap
may
involv
preferenti
translat
viral
mrna
influenza
infect
addit
interact
bound
conserv
region
utr
element
viral
mrna
could
promot
format
close
loop
end
viral
mrna
rigi
cytosol
receptor
nonself
rna
mediat
immun
respons
viral
infect
product
mitochondri
antiviralsign
mav
protein
tabl
show
inform
aptam
describ
influenza
viru
vaccin
power
approach
diminish
effect
influenza
epidem
use
antivir
drug
also
use
particularli
delay
spread
new
pandem
virus
neuraminidas
inhibitor
like
oseltamivir
laninamivir
zanamivir
peramivir
commonli
use
antivir
agent
treat
influenza
infect
especi
japan
howev
rapid
increas
drugresist
influenza
viru
essenti
develop
new
antivir
drug
emerg
strategi
block
cellular
factor
import
infect
cycl
advantag
block
import
cellular
pathway
viru
inhibitori
effect
principl
specif
influenza
strain
emerg
resist
viru
minim
limit
number
aptam
target
host
cell
factor
describ
use
rigi
target
aptam
control
viral
infect
emphas
rigi
cytosol
receptor
nonself
rna
mediat
immun
respons
viral
infect
product
use
specif
rigi
aptam
activ
rigi
effici
block
replic
newcastl
diseas
viru
vesicular
stomat
viru
influenza
viru
infect
cell
evidenc
aptam
target
cellular
factor
act
effici
antivir
agent
howev
aptam
direct
cellular
factor
establish
essenti
interact
influenza
viru
protein
report
mrna
influenza
viru
possess
cap
structur
poli
tail
make
structur
indistinguish
cellular
mrna
howev
select
translat
viral
mrna
occur
infect
cell
discriminatori
mechan
wherebi
viral
polymeras
interact
compon
translat
initi
complex
protein
thu
inhibit
viral
proteintransl
factor
interact
destabil
potenti
use
antivir
strategi
recent
rodriguez
et
al
studi
whether
two
aptam
bind
high
affin
abl
act
antiinfluenza
drug
aptam
inhibit
influenza
viru
replic
subtyp
high
low
multipl
infect
viral
interact
addit
aptam
inhibit
interact
result
indic
aptam
target
host
factor
interact
viral
protein
may
potenti
broad
therapeut
spectrum
reduc
appear
escap
mutant
resist
subtyp
emerg
viru
viru
adapt
emerg
new
diseasepathogen
strain
attribut
facilit
pathogen
field
normal
associ
viru
includ
virus
caus
diseas
notabl
increas
incid
often
result
wide
varieti
caus
influenc
man
natur
emerg
virus
categor
zoonot
anim
diseas
transmit
human
advantag
possibl
sever
natur
reservoir
diseas
virus
newli
appear
popul
exist
rapidli
increas
incid
geograph
rang
recent
aptam
emerg
virus
rift
valley
fever
tickborn
enceph
dengu
ebola
virus
arbovirus
develop
rift
valley
fever
viru
rvfv
mosquitoborn
bunyaviru
genu
phleboviru
respons
widespread
outbreak
sever
diseas
hepat
enceph
hemorrhag
fever
human
viru
endem
throughout
much
african
contin
howev
emerg
rvfv
middl
east
northern
egypt
comoro
archipelago
highlight
geograph
rang
rvfv
may
increas
led
concern
incurs
europ
may
occur
present
licens
human
vaccin
nucleocapsid
protein
n
rvfv
rna
bind
protein
requir
product
viabl
viru
involv
sever
stage
viral
replic
protein
protect
viral
genom
degrad
prevent
format
doubl
strand
rna
intermedi
replic
transcript
encapsid
viral
genom
antigenom
rna
ellenbeck
et
al
isol
rna
aptam
bound
n
high
affin
identifi
gauu
pyrimidineguanin
motif
sequenc
also
present
within
code
region
rvfv
genom
furthermor
author
develop
truncat
rna
aptam
label
fluorescein
use
fluoresc
polar
fp
system
titrat
n
famlabel
rna
aptam
gave
appar
kd
competit
bind
experi
conduct
four
differ
aptam
appar
ki
valu
nm
rang
data
demonstr
aptam
might
use
construct
sensit
fluoresc
base
sensor
n
bind
potenti
applic
drug
screen
imag
methodolog
tickborn
enceph
viru
tbev
belong
famili
flavivirida
genu
flaviviru
viru
produc
tickborn
enceph
tbe
import
emerg
infecti
diseas
target
central
nervou
system
cn
current
specif
antivir
treatment
tbe
specif
immunoglobulin
use
clinic
practic
sever
disadvantag
purpos
kondratov
et
al
obtain
aptam
popul
fragment
surfac
protein
e
tbev
sinc
avail
aptam
outsid
host
cell
author
show
treatment
librari
aptam
produc
tbev
neutral
index
compar
result
neutral
commerci
human
immunoglobulin
tickborn
enceph
npo
microgen
russia
addit
enzym
immunoassay
system
base
immobil
viral
particl
antibodi
commonli
use
tbev
diagnosi
author
claim
protein
e
aptam
could
substitut
antibodi
system
dengu
virus
denv
belong
flavivirida
famili
contain
four
serolog
genet
distinct
virus
term
envelop
e
protein
play
import
role
viral
infect
howev
effect
antibodi
clinic
treatment
due
antibodi
depend
enhanc
infect
chen
et
al
identifi
aptam
bind
envelop
protein
domain
iii
high
bind
affin
aptam
found
form
parallel
quadruplex
structur
togeth
sequenc
end
necessari
bind
activ
highli
conserv
loop
strand
although
aptam
select
author
demonstr
aptam
neutral
infect
four
serotyp
denv
denv
capsid
c
protein
function
structur
compon
infecti
virion
may
also
addit
function
viru
replic
cycl
balinski
et
al
show
denv
c
protein
interact
coloc
multifunct
host
protein
nucleolin
ncl
interact
disrupt
addit
ncl
bind
aptam
develop
aptamera
louisvil
ky
usa
treatment
cell
produc
signific
reduct
viral
titer
denv
infect
moreov
author
show
treatment
affect
migrat
characterist
viral
capsid
identifi
critic
interact
denv
c
protein
ncl
repres
potenti
new
target
develop
antivir
therapeut
technolog
point
view
aptam
use
effici
isol
endogen
assembl
viral
rnaprotein
complex
henc
dong
et
al
develop
affin
purif
strategi
base
rna
affin
tag
allow
largescal
prepar
nativ
viral
rnabind
protein
rbp
use
streptavidinbind
aptam
sequenc
insert
end
dengu
viru
denv
utr
rna
denv
rna
utr
fuse
rna
aptam
express
live
mammalian
cell
allow
endogen
viral
ribonucleoprotein
rnp
assembl
isol
rnp
whole
cell
extract
bind
aptam
streptavidin
magnet
bead
strategi
led
identifi
sever
novel
host
denv
rbp
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
includ
implic
denv
replic
ebola
viru
belong
genu
ebolaviru
four
five
known
virus
genu
caus
sever
often
fatal
hemorrhag
fever
human
mammal
known
ebola
viru
diseas
evd
ebola
viru
caus
major
human
death
evd
caus
ebola
viru
epidem
west
africa
viral
protein
multifunct
dsrna
bind
protein
play
import
role
viral
replic
innat
immun
evas
pathogenesi
multifunct
protein
offer
opportun
develop
molecul
target
distinct
function
region
purpos
bin
et
al
use
combin
structur
function
data
determin
region
ebola
viru
ebov
target
aptam
select
two
distinct
class
aptam
character
base
interact
properti
result
reveal
aptam
bind
distinct
region
high
affin
nm
specif
addit
author
show
aptam
compet
dsrna
bind
disturb
np
interact
consist
abil
antagon
interact
select
aptam
inhibit
function
ebov
polymeras
complex
reconstitut
express
select
viral
protein
mani
case
aptam
use
technolog
research
tool
identifi
rna
sequenc
recogn
differ
viru
protein
zincfing
antivir
protein
zap
host
factor
specif
inhibit
replic
moloney
murin
leukemia
viru
mlv
sindbi
viru
sin
ebola
viru
target
viral
mrna
degrad
prevent
accumul
cytoplasm
aim
identifi
rna
sequenc
could
target
zap
huang
et
al
use
aptam
technolog
identifi
grich
rna
aptam
contain
conserv
gggugg
gaggg
motif
loop
region
interestingli
overexpress
aptam
significantli
reduc
zap
antivir
activ
substitut
conserv
motif
aptam
significantli
impair
zapbind
abil
zapantagon
activ
suggest
rna
sequenc
import
specif
interact
zap
target
rna
sever
acut
respiratori
syndrom
sar
diseas
caus
sar
coronaviru
sarscov
caus
pandem
pneumonia
total
report
case
includ
death
countri
sarscov
belong
coronaviru
genu
coronavirida
famili
envelop
positivesens
rna
viru
genom
kilobas
rna
encod
two
larg
polyprotein
four
structur
protein
includ
spike
membran
envelop
e
nucleocapsid
n
protein
proteolyt
cleav
nonstructur
protein
nsp
form
viral
replicasetranscriptas
complex
review
sinc
sar
outbreak
sever
diagnost
assay
develop
base
rtpcr
elisa
use
biosensor
nucleocapsid
n
protein
target
choic
one
abund
structur
protein
dna
rna
aptam
n
protein
develop
kd
nm
respect
dna
aptam
effici
detect
n
protein
western
blot
suggest
could
altern
antibodi
ahn
et
al
develop
nanoarray
aptam
chip
rna
aptam
select
antigencaptur
agent
abl
detect
n
protein
concentr
low
pgml
studi
focus
develop
aptam
sarscov
antivir
spite
fact
still
effect
therapeut
treatment
viru
two
studi
select
dna
rna
aptam
nonstructur
protein
protein
possess
ntpase
duplex
rnadnaunwind
rnacap
activ
essenti
viral
replic
prolifer
aptam
inhibit
helicas
activ
subnanomolar
ic
atpas
activ
affect
suggest
aptam
may
bind
nucleic
acid
bind
site
helicas
block
unwind
activ
tabl
show
inform
aptam
describ
emerg
virus
sever
acut
respiratori
syndrom
nd
dnarna
nonstructur
protein
nd
determin
aptam
technolog
began
develop
earli
seen
major
success
last
year
howev
despit
number
aptam
use
clinic
practic
limit
probabl
due
ignor
still
exist
toward
technolog
advantag
antibodi
mani
diagnost
therapeut
applic
inde
aptam
molecul
extraordinari
potenti
field
viral
diseas
number
drug
treat
infect
small
avail
therapeut
effect
addit
current
diagnost
tool
viral
infect
expens
time
consum
import
diagnost
therapeut
limit
favor
develop
aptamerbas
system
mainli
show
sever
interest
advantag
relat
antibodi
thu
aptam
recogn
andor
inhibit
target
activ
specif
strong
interact
superior
biolog
small
molecul
therapeut
lower
toxic
immunogen
profil
sens
last
year
aptam
technolog
use
wide
rang
diagnost
therapeut
applic
associ
viral
patholog
signific
aptam
select
specif
antivir
molecul
effect
infect
cell
howev
none
select
antivir
aptam
enter
clinic
trial
conclus
necessari
continu
research
studi
success
develop
clinic
trial
establish
use
aptam
antivir
success
treatment
viral
diseas
depend
earli
detect
infect
agent
probabl
use
aptam
viru
diagnost
involv
develop
simpl
fast
cheap
diagnost
devic
one
simpl
detect
system
later
flow
immunoassay
lfia
current
use
qualit
monitor
resourcelimit
nonlaboratori
environ
lfia
biosens
platform
mainli
compris
sampl
pad
test
pad
gener
compos
nitrocellulos
membran
provid
platform
reaction
detect
captur
molecul
antibodi
later
flow
biosens
platform
develop
use
aptam
hepat
c
viru
hcv
core
antigen
could
appli
hiv
emerg
viru
detect
use
aptam
specif
protein
method
allow
detect
virus
endem
transit
human
area
anoth
interest
approach
obtain
cheaper
diagnosticsgenotyp
devic
use
one
aptam
detect
sever
target
point
view
strategi
wang
et
al
use
conform
chang
one
aptam
expos
differ
ion
concentr
detect
multipl
type
influenza
viru
could
use
genotyp
virus
hbv
hcv
therapeut
point
view
aptam
offer
hope
solut
viral
diseas
target
element
viru
infect
host
cell
easier
antibodi
mainli
due
small
size
potenti
design
aptam
work
differ
target
might
block
virion
penetr
cell
inhibit
enzym
respons
viral
replic
critic
process
case
despit
effici
antiretrovir
therapi
erad
latent
proviru
challeng
requir
novel
biolog
insight
therapeut
strategi
aim
novel
target
protein
chosen
hiv
reservoir
organ
isol
aptam
could
appli
drug
deliveri
target
nanoparticl
load
drug
obtain
hiv
transcript
activ
alreadi
mention
rigi
use
target
aptam
control
viral
infect
recent
olagni
et
al
investig
inhibitori
effect
rigi
agonist
replic
dengu
chikungunya
virus
author
demonstr
rigi
stimul
gener
protect
antivir
respons
pathogen
would
motiv
studi
use
rigi
aptam
develop
hwang
dengu
chikungunya
therapi
likewis
effect
aptam
develop
guerra
et
al
pabp
decreas
replic
influenza
viru
could
studi
virus
also
use
pabp
infect
cell
nanoparticl
consid
wide
rang
applic
solubl
insolubl
form
advantag
solubl
form
nanoparticl
encapsul
antibioticsdrug
releas
reach
cellular
environ
make
highli
applic
drug
deliveri
system
studi
aptamerbas
enhanc
drug
deliveri
report
prostat
cancer
lymphoblast
leukemia
cell
purpos
hiv
therapi
nanoparticl
success
load
antiretrovir
arv
drug
effici
inhibit
infect
result
show
benefit
nanoparticl
applic
deliveri
antivir
drug
improv
bioavail
conclus
use
aptam
develop
diagnost
platform
therapeut
drug
promis
altern
treatment
viral
diseas
